American Association for Cancer Research
can-21-1859_supplementary_table_s8_suppst8.xls (79.5 kB)

Supplementary Table S8 from Antisense RNAs Influence Promoter Usage of Their Counterpart Sense Genes in Cancer

Download (79.5 kB)
posted on 2023-04-03, 20:26 authored by Fernando Bellido Molias, Andre Sim, Ka Wai Leong, Omer An, Yangyang Song, Vanessa Hui En Ng, Max Wei Jie Lim, Chen Ying, Jasmin Xin Jia Teo, Jonathan Göke, Leilei Chen

List of 521 unique ncNATs expressed in non-tumor samples of one or multiple cancer/tissue types from TCGA and GTEx.


Ministry of Education - Singapore (MOE)

National Medical Research Council (NMRC)



Multiple noncoding natural antisense transcripts (ncNAT) are known to modulate key biological events such as cell growth or differentiation. However, the actual impact of ncNATs on cancer progression remains largely unknown. In this study, we identified a complete list of differentially expressed ncNATs in hepatocellular carcinoma. Among them, a previously undescribed ncNAT HNF4A-AS1L suppressed cancer cell growth by regulating its sense gene HNF4A, a well-known cancer driver, through a promoter-specific mechanism. HNF4A-AS1L selectively activated the HNF4A P1 promoter via HNF1A, which upregulated expression of tumor suppressor P1-driven isoforms, while having no effect on the oncogenic P2 promoter. RNA-seq data from 23 tissue and cancer types identified approximately 100 ncNATs whose expression correlated specifically with the activity of one promoter of their associated sense gene. Silencing of two of these ncNATs ENSG00000259357 and ENSG00000255031 (antisense to CERS2 and CHKA, respectively) altered the promoter usage of CERS2 and CHKA. Altogether, these results demonstrate that promoter-specific regulation is a mechanism used by ncNATs for context-specific control of alternative isoform expression of their counterpart sense genes. This study characterizes a previously unexplored role of ncNATs in regulation of isoform expression of associated sense genes, highlighting a mechanism of alternative promoter usage in cancer.

Usage metrics

    Cancer Research